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Background: Metformin, the most widely used drug for type 2 diabetes, has recently attracted attention with
regard to its antitumor activity. However, clinical studies have yielded conflicting results regarding the asso-
ciation between metformin and thyroid cancer development, despite its antitumor effect in preclinical studies.
Methods: This is a retrospective cohort study using the Korean National Health Insurance claim database.
Matched populations of 128,453 metformin users and 128,453 non-users were analyzed for thyroid cancer
incidence. Metformin users were categorized into lowest, middle, and highest tertiles according to cumulative
dose or duration of metformin therapy.
Results: Thyroid cancer developed in 340 (0.26%) metformin users and 487 (0.38%) non-users during a mean
follow-up of 7.2 years (hazard ratio= 0.69 [confidence interval 0.60–0.79]; p< 0.001). The incidence of thyroid
cancer per 105 person-years was 51.6 in metformin non-users. For metformin users, the incidence was 84.5 for
<529,000mg, 20.6 for 529,000–1,007,799mg, and 6.3 for >1,007,799mg; 86.3 for <1085 days, 20.3 for 1085–
2094 days, and 4.7 for >2094 days for duration of therapy. The hazard ratio for thyroid cancer decreased
significantly in metformin users as a function of dose and duration of metformin therapy.
Conclusions: Metformin appears to be associated with a preventive effect on thyroid cancer development in a
nationwide population-based study, but is not effective in the early phase of treatment. Considering the in-
creasing prevalence of obesity and the role of insulin resistance in the development of cancer, metformin might
be the preferred treatment for its dual anti-diabetic and antitumor effects.
Keywords: metformin, thyroid cancer, protective effect, population-based study
Introduction
D iabetes is the most prevalent disease in endocrinologyand is associated with an increased risk of cancer de-
velopment. The incidence of several types of cancers, in-
cluding colon (1), breast (2), and pancreas (3) cancer, is
known to be elevated in patients with type 2 diabetes. A
recent study reported a greater risk of all-cause cancers in
middle-aged diabetic patients (4). The incidence of thyroid
cancer has rapidly increased worldwide in recent decades
(5,6). Although the introduction of imaging studies such as
ultrasonography have contributed to the detection of small
thyroid cancers (5), the increase in thyroid cancers is not fully
explained by increased diagnosis and screening alone (6).
Other factors such as insulin resistance have been suggested
to be factors contributing to cancer development (7,8) as the
prevalence of obesity and diabetes increase. The diagnosis of
a malignancy adds an additional burden for diabetic indi-
viduals and their societies.
Metformin is the most widely used drug for the treatment
of type 2 diabetes, with approximately 120 million pre-
scriptions per year globally (9). Aside from its anti-diabetic
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effect, experimental studies have revealed antitumor effects
of metformin. Metformin reduces circulating insulin by en-
hancing insulin sensitivity and decreasing hepatic gluco-
neogenesis. In addition, metformin inhibits the mammalian
target of rapamycin (mTOR) pathway via activation of AMP-
activated protein kinase (AMPK), which leads to the inhibi-
tion of protein synthesis and cell proliferation (10). Previous
studies observed that metformin inhibits thyroid cancer cell
growth and induces cell-cycle arrest and apoptosis through
AMPK activation and mTOR inhibition in vivo and in vitro
(11,12).
However, epidemiologic studies examining the antitumor
effect of metformin on thyroid cancer failed to give consistent
results. Tseng et al. reported a protective effect of metformin
on thyroid cancer risk in a Taiwanese population with type 2
diabetes compared to metformin never-users (hazard ratio
[HR]= 0.683 [confidence interval (CI) 0.598–0.780]) (13). To
date, this study is the only epidemiologic study reporting the
protective effect of metformin on thyroid cancer development,
although their results were weakened by insufficient definition
of metformin user and duration of drug exposure. Two sub-
sequent studies conducted inWestern populations observed no
relationship between metformin exposure and thyroid cancer
development (14,15). The small proportion of diabetic subjects
in their studies—5.7% (14) and 15.8% (15), respectively—
could be the reason for the results.
There is less evidence for the beneficial effect of metfor-
min on thyroid cancer development than for other types of
cancer. Therefore, this study investigated the association
between metformin exposure and thyroid cancer incidence in
newly diagnosed type 2 diabetic individuals using the National
Health Insurance (NHI) claim database in Korea, which covers
the entire population.
Methods
Data source
Data from the NHI claim database of Korea were used. The
NHI is the only public medical insurance system in Korea and
represents the entire Korean population because of the com-
pulsory social insurance system that is required by law. All
clinics and hospitals in Korea submit data on inpatients and
outpatients, including information on diagnosis and medical
costs, to the NHI to claim payments for patient care (16).
Study population
This study enrolled newly diagnosed diabetic subjects
aged ‡30 years who had been prescribed anti-diabetic drug(s)
at least twice between January 2005 and December 2009. To
enroll subjects with new-onset diabetes only, individuals
with previous claims for any anti-diabetic drugs or a coding
of diabetes in a three-year washout period before January
2005 were excluded. Subjects with claims for insulin pre-
scriptions more than twice in the study period were also ex-
cluded to rule out the possible effect of insulin on the
development and growth of thyroid cancer, as were individ-
uals who had been followed up for <180 days. The protocol
was reviewed and approved by the Institutional Review
Board of National Health Insurance Service Ilsan Hospital
(NHIMC 2016-03-004).
Definition of metformin exposure
Metformin users were defined as subjects who had been
prescribed with metformin for at least 180 days during
365 days. Metformin non-users were defined as subjects
who had never been prescribed metformin or who did not
satisfy the definition of metformin user (metformin use for
<180 days) during the whole study period (from January 2005
to December 2014). Among 570,759 metformin users and
145,481 metformin non-users, the users and non-users were
matched by five covariates: age, sex, income, living area, and
anti-diabetic drugs other than metformin. This resulted in
128,453 metformin users and 128,453 metformin non-users
for analysis in this study. To assess the effect of metformin on
thyroid cancer incidence according to cumulative dose and
duration, the sum of prescribed dose (mg per day· days) and
the duration (days) of metformin use in each person were
calculated, and subjects were divided into three groups (ter-
tiles) for prescribed dose or duration.
Detection of thyroid cancer
Thyroid cancer is classified with code C73.9 according to
the International Classification of Diseases, 10th edition
(ICD-10) (17). Diagnosis of thyroid cancer was defined by a
claim for any type of thyroidectomy with a coding of thyroid
cancer between January 2005 and December 2014. To assess
the incidence of newly developed thyroid cancer, individuals
who had claimed for thyroid cancer before study enrollment
were excluded. Subjects with claims for thyroid cancer be-
fore the diagnosis of diabetes were also excluded. Follow-up
duration was calculated from the date of study enrollment to
diagnosis of thyroid cancer or death or the end date of this
study, which was December 2014.
Covariates
Age groups were categorized using five-year intervals
starting at 30 years of age. As newly diagnosed diabetic pa-
tients were selected using a three-year washout period, the
year of enrollment was regarded as the year of diagnosis with
diabetes or the beginning of anti-diabetic medication. Income
groups were divided into 20 classes and reclassified into four
groups. Living area was classified into three groups: Seoul
(capital city), metropolitan city (Busan, Daegu, Incheon,
Gwangju, Daejeon, and Ulsan), and rural area. Anti-diabetic
drugs other than metformin included sulfonylureas, thiazoli-
dinediones, dipeptidyl peptidase-4 inhibitors, and alpha glu-
cosidase inhibitors. Information for these drugs was assessed
by claim records.
Statistical analysis
Subjects were classified into two groups: metformin users
and metformin non-users. The incidence of thyroid cancer is
presented as number of events per 100,000 person-years
(PY). The HR and CI between two groups of interest were
calculated using Cox proportional hazards regression, with
adjustment for age, sex, year of study enrollment, income,
living area, and anti-diabetic drugs other than metformin. A
p-value of <0.05 was considered to indicate a statistically
significant result. All analyses were conducted using statis-
tical software SAS v9.4 (SAS Institute, Cary, NC).
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Results
Demographics
This study consisted of 128,453 metformin non-users and
128,453 metformin users. Their demographics, including
age, sex, year of study enrollment, income, living area, and
anti-diabetic drugs other than metformin, are presented in
Table 1. Metformin users tended to be older (Mage = 62 years
vs. 61 years), female (50.4% vs. 48.8%), earn more income,
and live in a capital city compared to metformin non-users.
In metformin users, the M – SD daily prescribed dose of
metformin was 531– 161mg, M– SD cumulative duration
was 1633– 915 days, and M– SD cumulative dose was
868,169– 563,221mg. The duration between starting metfor-
min and diagnosis of thyroid cancer was longer in metformin
users than that of metformin non-users (37.2 vs. 31.5 months).
Thyroid cancer incidence in diabetic subjects
according to metformin use
During a 7.2-year mean follow-up duration in each group,
487 (0.38%) thyroid cancers were detected in metformin non-
users compared to 340 (0.26%) in metformin users. The in-
cidence rate of thyroid cancer per 100,000 PY was 51.6 in the
metformin non-users (reference) and 36.1 in the metformin
users. Multiple-adjusted HR indicated that metformin users
had a lower risk for thyroid cancer incidence than metformin
non-users (HR = 0.69 [CI 0.60–0.79]; p < 0.001; Table 2).
When calculating HR according to cumulative dose and
duration of metformin, a dose- or duration-dependent pro-
tective effect on thyroid cancer development was observed.
Risk for thyroid cancer was reduced in metformin users
with middle (529,000–1,007,799mg) or highest tertiles
(>1,007,799mg) of cumulative dose compared to metformin
non-users (HR= 0.37 [CI 0.28–0.48]; p< 0.001; and HR= 0.11
[CI 0.07–0.17]; p< 0.001). Users who had been prescribed
metformin for a longer duration developed thyroid cancer
less frequently than metformin non-users (cumulative days
of metformin use 1085–2094 days; HR= 0.36 [CI 0.27–0.47];
p < 0.001; and >2094 days; HR= 0.08 [CI 0.05–0.13];
p< 0.001). However, the lowest tertiles of cumulative metfor-
min dose (<529,000mg) or duration (<1085 days) were at
higher risk of thyroid cancer incidence compared to metformin
non-users (HR= 1.79 [CI 1.53–2.08]; p< 0.001; and HR= 1.86
[CI 1.60–2.16]; p< 0.001). The chi-square test for trend showed
a significant association between dose or duration of metformin
use and the development of thyroid cancer (both p< 0.001).
Thyroid cancer risks were reduced significantly in both sexes
(male: HR= 0.68 [CI 0.51–0.92]; p= 0.01; and female:
HR= 0.65 [CI 0.56–0.76]; p< 0.001) and in middle-aged sub-
jects (aged 50–64 years; Supplementary Tables S1 and S2).
Discussion
This study examined the protective effect of metformin
on thyroid cancer development based on a nationwide
population-based database. A significant associationwas found
between the use of metformin and thyroid cancer, especially in
diabetic individuals takingmetforminwith a higher cumulative
dose (‡529,000mg) or for a longer duration (‡1085 days). In
contrast, no protective effect was observed for a lower cumu-
lative dose or during the early period of metformin use.
A considerable number of studies demonstrated the an-
ticarcinogenic effect of metformin in thyroid cancer de-
velopment using preclinical data. Chen et al. reported an
anti-mitogenic effect of metformin on thyroid cancer cells
and thyroid cancer stem cells through inhibition of cell-cycle
progression and induction of apoptosis (11). Cho et al. sug-
gested the therapeutic potential of a physiologic dose of
metformin in vivo and in vitro (12). The viability of thyroid
cancer cells was inhibited and cell apoptosis was increased
for various doses of metformin (0.5–20mM), and the
p-AMPK/AMPK ratio was activated and mTOR expression
was suppressed in metformin-treated mice compared to
control mice. The antitumor effect of metformin occurs by
direct and indirect mechanisms (18). Signaling of mTOR
induces protein synthesis and tumorigenesis, and metformin
inhibits mTOR activity directly or via AMPK activation. In
addition, metformin increases insulin sensitivity and sup-
presses hepatic gluconeogenesis, which results in a decreased
level of circulating insulin. As a high concentration of serum
insulin stimulates mTOR signaling, metformin is expected to
inhibit mTOR expression in an indirect manner.
In contrast to preclinical research, clinical studies regard-
ing the antitumor effect of metformin on thyroid cancer have
presented conflicting results. Tseng et al. reported a 32% risk
reduction of thyroid cancer in patients with metformin ex-
posure in a Taiwanese population (13). Their results are
comparable to the present data (a 31% risk reduction).
However, they observed a diminished risk of thyroid cancer
in the early period of metformin exposure (<9 months or
<263,000mg of metformin use). Although six-month treat-
ment with metformin induced a remarkable volume reduction
of benign thyroid nodules (median reduction of 108.5mm3,
-30%, p < 0.008) in a prospective study (n = 14) (19), the
effect of short-term use of metformin on thyroid nodules,
including carcinomas, needs to be investigated considering
that the natural growth of thyroid nodules is <1mm growth in
the largest diameter per year (20). The previous study by
Tseng et al. has been criticized for the study design, as they
defined metformin exposure based on prescription history
prior to study entry and did not assess changes in metformin
exposure during the study period. In the present study, the
authors tried to examine the exact dose and duration of
metformin exposure in each subject using a reliable claim
database. Two consecutive studies, a case control study (14)
and a prospective cohort study (15), reported no association
between metformin and thyroid cancer risk (HR = 1.48 [CI
0.86–2.54]and HR= 1.09 [CI 0.79–1.52], respectively). These
well-designed studies considered covariates for thyroid cancer
such as alcohol consumption, smoking, and obesity. However,
the majority of their study populations comprised non-diabetic
individuals. Thus, the small number of diabetic patients with
metformin exposure brings the negative results of their studies
into question.
The present data demonstrate a protective effect of met-
formin on thyroid cancer development in a dose- or duration-
dependent manner. For example, three-year use of metformin
with 500mg per day is expected to have a preventive effect
for thyroid cancer. Interestingly, metformin users had a
longer duration between starting metformin and thyroid
cancer diagnosis than metformin non-users (mean duration of
37.2 months vs. 31.5 months), possibly supporting a pre-
ventive effect of metformin on thyroid cancer development.
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Table 1. Demographics of Subjects According to Metformin Use
Variables
Metformin
non-user (N= 128,453)
Metformin
user (N = 128,453)
n % n %
Age (years), M – SD* 61 – 15 62– 14
30–34 3523 2.8 1535 1.2
35–39 4973 3.9 3661 2.8
40–44 7784 6.1 6661 5.2
45–49 12,252 9.5 11,513 9.0
50–54 14,092 11.0 14,580 11.4
55–59 15,093 11.7 16,305 12.7
60–64 16,219 12.6 17,924 14.0
65–69 18,022 14.0 19,811 15.4
70–74 15,731 12.2 16,632 12.9
75–79 11,527 9.0 11,419 8.9
‡80 9237 7.2 8412 6.5
Sex, male* 65,746 51.2 63,733 49.6
Year of study enrollment*
2005 30,471 23.7 28,251 22.0
2006 26,389 20.6 25,480 19.8
2007 25,053 19.5 25,498 19.9
2008 24,570 19.1 25,874 20.1
2009 21,970 17.1 23,350 18.2
Thyroid cancer cases* 487 0.38 340 0.26
Year of diagnosis of thyroid cancer*
2005 2 0.4 0 0
2006 25 5.1 15 4.4
2007 85 17.5 31 9.1
2008 149 30.6 70 20.6
2009 84 17.2 76 22.4
2010 42 8.6 37 10.9
2011 36 7.4 35 10.3
2012 26 5.3 35 10.3
2013 26 5.3 21 6.2
2014 12 2.5 20 5.9
Follow-up duration (years), M– SD 7.2 1.8 7.2 1.6
Duration between starting metformin and
diagnosis of thyroid cancer (months), M –SD*
31.5 21.1 37.2 23.2
Income*
1–5 (lowest) 39,472 30.7 37,885 29.5
6–10 23,625 18.4 23,255 18.1
11–15 29,462 22.9 29,750 23.2
16–20 (highest) 35,894 28.0 37,563 29.2
Living area*
Seoul (capital city) 27,606 21.5 28,734 22.4
Metropolitan city 32,127 25.0 32,137 25.0
Rural area 68,720 53.5 67,582 52.6
Anti-diabetic drugs
Sulfonylurea*
Yes 61,172 47.6 62,679 48.8
No 67,281 52.4 65,774 51.2
Thiazolidinedione*
Yes 5228 4.1 5426 4.2
No 123,225 95.9 123,027 95.8
DPP-4 inhibitor*
Yes 2375 1.8 2460 1.9
No 126,078 98.2 125,993 98.1
Alpha glucosidase inhibitor*
Yes 11,403 8.9 10,404 8.1
No 117,050 91.1 118,049 91.9
Variables are presented as number (n) and percentage (%), except for age, follow-up duration, and the duration between starting
metformin and diagnosis of thyroid cancer. Metformin non-users were defined as subjects who had never been prescribed with metformin or
did not satisfy the definition of metformin user during the study period. Metformin users were defined as subjects who had been prescribed
with metformin for at least 180 days during 365 days. Follow-up duration was similar in metformin users and non-users ( p = 0.49).
*p < 0.001.
SD, standard deviation; DPP-4 inhibitor, dipeptidyl peptidase-4 inhibitor.
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Lin et al. also reported a dose-dependent effect of metformin
on cancer risk and cancer onset time using a longitudinal
health insurance database. Diminished cancer risk was sig-
nificant with a >360 defined daily dose (equal to 720,000mg)
of metformin (HR = 0.40 [CI 0.24–0.66]; p < 0.001) com-
pared to diabetic patients who did not receive anti-diabetic
medication (21), and their results were comparable with the
data in the present study, although they did not analyze the
cancer risk by cancer subtype.
Themajority of thyroid cancers are detected as small masses
and have a good prognosis, which has led to changes in the
concept of treatment toward adopting less aggressive surgery,
including lobectomy only (22). Moreover, active surveillance
is suggested as one of the treatment strategies for early-stage
thyroid cancers in selected patients instead of surgery (22).
Inhibition of development or progression of thyroid cancer can
keep tumors in an indolent state, and in this regard, metformin
might be a promising candidate because of its antitumor effect.
Because the effect of metformin is not as potent as that of
therapeutic agents used for chemotherapy, demonstrating a
preventive effect against carcinogenesis is challenging, espe-
cially in studies with insufficient sample sizes (14,15), which
has resulted in controversies. Whether metformin delays
sprouting or progression of thyroid cancer might be an inter-
esting topic for further studies.
These promising results cannot be applied to all diabetic
subjects because of the varied disease status of diabetes and
the effect of other medications, including insulin. Patients
with advanced diabetes and comorbidities usually take mul-
tiple medications. In these patients, disease status, as well as
medications, may affect sensitivity to insulin action or cancer
development. Some authors have suggested a relationship
between elevated risks of cancers and insulin or sulfonylurea
therapy, probably due to their effects of increasing insulin
levels (23,24). However, Lin et al. reported a reduced cancer
risk, even in patients taking metformin combined with other
anti-diabetic medication (21). In another study by Tseng
et al., a reduced risk for thyroid cancer was reported in
subjects with early diabetes (duration of diabetes <5 years),
whereas the effect was neutralized in individuals with a
longer diabetes duration (23). Thus, the study subjects were
limited to people who had newly diagnosed diabetes or
started taking anti-diabetic medication except for insulin to
minimize the heterogeneity of the study population.
An increased risk of thyroid cancer was observed in the
early period of metformin use. As metformin reduces insulin
resistance and has a neutral effect onweight gain, metformin is
preferred for obese diabetic patients. The prevalence of obesity
in the Korean population has increased rapidly, especially in
adult men (body mass index [BMI] ‡25kg/m2, from 32.4% in
2001 to 36.7% in 2007) (25). Obesity has been suggested as
one of the risk factors for thyroid cancer (26). In fact, the
clinical characteristics of metformin users can be linked with
risk factors of thyroid cancer. In a mouse model, a high-fat diet
aggravates thyroid cancer progression via activation of the
leptin-JAK2-STAT3 signaling pathway (27), whereas met-
formin blocks progression of obesity-activated thyroid cancer
(28). It was cautiously assumed that the demographics of
metformin users, including obesity, also increase the risk of
thyroid cancer, and that the decreased insulin resistance due to
metformin may have a protective effect on cancer develop-
ment, although data for BMI or obesity were not available.
Metformin users had a tendency to earn a higher income and
live in the capital city than metformin non-users, and these
socioeconomic factors might promote thyroid cancer detection
through thyroid screening. Due to the limitation of the retro-
spective design and the prevalence of thyroid screening in
Korea during the study period, an uncorrectable bias caused by
thyroid screening may affect the thyroid cancer incidence,
especially in the early phase of metformin use. However, an
attempt was made to adjust covariates in multiple regression
analysis, and it was found that the protective effect of met-
formin remained significant.
In subgroup analysis, both females and males, especially
middle-aged diabetic subjects, gained a protective effect
from metformin on thyroid cancer development. Previous
Table 2. Hazard Ratio for Thyroid Cancer Incidence in Diabetic Subjects by Metformin Use
Metformin use
Diabetic
subjects
Thyroid cancer
case
Person-
year
Incidence
rate of thyroid
cancer (%)
Incidence of
thyroid cancer
(per 100,000
person-years)
Hazard ratio
of thyroid
cancer [CI]
Non-user 128,453 487 943,036 0.38 51.6 Reference
User 128,453 340 941,334 0.26 36.1 0.69 [0.60–0.79]*
Cumulative dose (mg)
<529,000 41,921 256 302,812 0.61 84.5 1.79 [1.53–2.08]*
529,000–
1,007,799
43,566 63 305,157 0.14 20.6 0.37 [0.28–0.48]*
>1,007,799 42,966 21 333,365 0.05 6.3 0.11 [0.07–0.17]*
Cumulative duration of therapy (days)
<1085 42,218 264 305,889 0.63 86.3 1.86 [1.60–2.16]*
1085–2094 42,777 60 295,829 0.14 20.3 0.36 [0.27–0.47]*
>2094 43,458 16 339,616 0.04 4.7 0.08 [0.05–0.13]*
Metformin non-users were defined as subjects who had never been prescribed with metformin or did not satisfy the definition of
metformin user during the study period. Metformin users were defined as subjects who had been prescribed with metformin for at least
180 days during 365 days. Hazard ratio was adjusted by age, sex, year of study enrollment, income, living area, and anti-diabetic drugs
other than metformin.
*p < 0.001, compared with metformin non-user (reference).
CI, confidence interval.
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studies, including epidemiologic data (13–15), did not sug-
gest specific groups that may benefit frommetformin in terms
of thyroid cancer development. The age-specific effect of
metformin on cancer development has not been reported in
the literature, and both diabetes and thyroid cancer are
prevalent in middle-aged subjects (aged 50–64 years). Thus,
the preventive effect of metformin seems to reach a statisti-
cally significant value in middle-aged subjects compared to
other age groups.
This study had several limitations. First, due to its retro-
spective design and the limitation of the NHI claim data set, it
was not possible to control for biases or obtain additional
information related to thyroid cancer incidence such as
screening of thyroid disease, personal or family history of
thyroid disease, drinking, smoking habits, and obesity. To set
a comparable control group, metformin non-users rather than
healthy subjects were defined as controls with consideration
of shared common characteristics among the diabetic popu-
lation. In addition, metformin users and non-users were
matched at baseline, and a multiple regression test was used
adjusting for available parameters. Second, this study has a
relatively short follow-up duration considering the indolent
progression of thyroid cancer. Clinical studies for the pro-
tective effect of metformin on thyroid cancer are scarce. In an
earlier study, Gwiezdzinska et al. reported a smaller tumor
size and a higher remission rate of thyroid cancer in diabetic
patients taking metformin, with a 4.4-year of mean treatment
than metformin non-users (29). Insulin users were excluded,
and the present data have a short follow-up duration (7.2
years) compared to two prospective studies of 11 (14) and 15
years (15). However, the present data have a longer PY du-
ration (1,884,370 PY). Third, the effect of metformin on
aggressiveness of thyroid cancer could not be assessed be-
cause of the lack of information on cancer histology, stage, or
disease-specific death, although this issue is beyond the scope
of this study. Two studies suggested that metformin use was
related to a better prognosis of thyroid cancer, a higher re-
mission rate (29), and a lower recurrence rate of cervical
lymph node metastasis (30) in thyroid cancer patients, but
this needs to be validated in future studies. Finally, infor-
mation on drug adherence was not available, although sub-
optimal adherence for anti-diabetic drugs has been reported
in patients with type 2 diabetes (31).
In conclusion, this study reports a significant association
between metformin use and a decreased risk of thyroid cancer
development using a nationwide population-based database.
As the first choice of anti-diabetic drug in the majority of new
patients with type 2 diabetes, metformin is expected to have a
preventive effect on the development of thyroid cancer in
addition to its glucose-lowering effect.
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